<DOC>
	<DOCNO>NCT01372787</DOCNO>
	<brief_summary>This clinical trial study quality life care need patient persistent recurrent ovarian cancer , fallopian tube cancer , peritoneal cancer . Studying quality life patient cancer may help determine effect gynecologic cancer may help improve quality life future cancer survivor .</brief_summary>
	<brief_title>Quality Life Care Needs Patients With Persistent Recurrent Ovarian Cancer , Fallopian Tube Cancer , Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine prevalence severity patient-reported symptom patient platinum-resistant ovarian , fallopian tube , peritoneal cancer study entry three six month post-enrollment . SECONDARY OBJECTIVES : I . To explore unmet need woman study entry three six month post-enrollment ( Exploratory ) II . To explore overall quality-of-life ( QOL ) woman study entry three six month post enrollment . ( Exploratory ) III . To explore relationship patient-reported symptom overall QOL , current cancer therapy ( yes/no ) , treatment response ( cancer therapy ) . ( Exploratory ) OUTLINE : This multicenter study . Patients complete Needs End-of-Life Screening Tool ( NEST ) , Functional Assessment Cancer Therapy - Ovarian ( FACT-O ) , FACIT-Fatigue Subscale ( FACIT-F ) , National Comprehensive Cancer Network ( NCCN ) FACT Ovarian Symptom Index-18 ( NFOSI-18 ) , FACT/GOG-AD subscale ovarian cancer-related abdominal discomfort , FACT/GOG-Neurotoxicity ( FACT/GOG-NTX ) Scale quality-of-life questionnaire baseline 3 6 month office clinic visit via telephone mail . Patients ' demographic therapy information , current age , ethnicity , marital status , employment status , prior chemotherapy regimens/cancer treatment , disease status ( available ) , performance status , patient care information , current cancer therapy also collect . After completion study participation , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>Patients persistent recurrent epithelial ovarian cancer , peritoneal cancer , fallopian tube cancer Platinumresistant ( less 6 month date last platinum therapy date first evidence recurrent persistent disease ) disease measure follow : Imaging Physical exam CA125 twice upper limit normal two occasion least one week apart No patient platinum resistant refractory disease 6 month since prior therapy Criteria patient cancer therapy ( e.g. , chemotherapy , noncytotoxic regimen , hormone therapy , radiation therapy ) include recurrent persistent disease define measurable disease per RECIST ( Version 1.1 ) Patients chemotherapy also eligible require RECIST criterion Life expectancy least 6 month Patients performance status , yet ability verbally consent participate first assessment Study measure administer office/clinic setting , study participant unable attend clinic , via telephone mail ( telephone prefer backup mean ) Patients may prior nongynecologic malignancy within 5 year prior study enrollment ; however , must complete treatment disease evidence disease time enrollment , ovarian , peritoneal , fallopian tube cancer must primary lifethreatening diagnosis Patient must able read write English No patient receive chemotherapy platinumsensitive ovarian cancer , peritoneal , fallopian tube cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>